Biovica International AB (publ)

BIOVIC-B · Nasdaq Stockholm · Healthcare

0.31SEK +2.3%last day

Price as of 2 October 2026

The price over the past year, with dividends: −50.0%

Performance

1 month

−27.4%

1 year

−50.0%

3 years, per year

−65.6%

5 years, per year

−63.8%

Largest fall, 3 years

−98.4%

Below the peak now

−99.5%

Volatility, 1 year

86.1%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

1.3

Dividend yield

0.0%

Return on equity

−108.5%

Net margin

−135.4%

Market value

9 m USD

Quality, value and trend

Where Biovica International stands against every Nordic stock today. 100 is best.

Quality69

Profitability and a sound balance sheet over time. Better than 69% of Nordic stocks.

Value17

The price measured against earnings, assets and cash flow. Better than 17% of Nordic stocks.

Trend13

The price development over the past year. Better than 13% of Nordic stocks.

Combined17

Quality, value and trend together. Better than 17% of Nordic stocks.

About Biovica International

Biovica International AB (publ) is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 24 employees.

Biovica International AB (publ), a biotech company, develops and commercializes blood-based biomarker assays for oncologists monitor cancer progression in the European Union, the United States, and Asia. The company engages in the development of DiviTum TKa, a monitoring tool for patients with early or metastatic breast cancer undergoing treatment with CDK4/6 inhibitors. It serves cancer institutes and pharmaceutical companies. The company was incorporated in 2008 and is headquartered in Uppsala, Sweden.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis